| Output | Title | Journal/Conference | Date Published | Publication Link |
| CST2 | Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, open-label, dose-escalating, randomised controlled study | International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021 | 20 September 2021 | Read More |
| CST3A | An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for treatment of COVID-19 | International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021. Oral | 20 September 2021 | Read More |
| CST2 | Saliva, nasal & tear PK of EIDD-1931 in patients with COVID-19 receiving molnupiravir | CROI 2021 | 15 February 2022 | Read More |
| Platform | The AGILE Platform: Accelerating phase I/II evaluation of SARS-CoV-2 antivirals | International Pandemic Sciences Conference | 10-11th July 2023 | |
| CST8 | Saliva, nasal & tear PK of ritonavir-boosted nirmatrelvir (Paxlovid) in combination with molnupiravir in patients with laboratory-confirmed COVID-19 | International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs | 11-13th September 2023 | |
| CST6 | Development, validation and application of a novel LC-MS method for quantification of favipiravir ribofuranosyl-5’-triphosphate (F-RTP) in human peripheral blood mononuclear cells (PBMCs) | International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs | 11-13th September 2023 | |
| CST5 | A randomised, adaptive Phase I study to determine the Phase II dose of Vir-7832: AGILE CST5 | CROI 2024 | 3-6th March 2024 | |
| CST8 | AGILE CST-8 Phase I Trial of Combined Nirmatrelvir/r and Molnupiravir for COVID-19 | CROI 2024 | 3-6th March 2024 | |
| CST6 | Favipiravir Pharmacokinetics in Saliva, Tears and Nasal Secretions of Hospitalised COVID-19 Patients Following Intravenous Favipiravir Administration | International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs | 18-19th September 2024 | |
| CST6 | Intracellular Pharmacokinetics of Favipiravir-5’- Ribofuranosyl Triphosphate in People with COVID-19 | CROI 2025 | 9-12th March 2025 | |
| Platform | AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial | Trials | 19 June 2020 | Read more |
| CST2 | Optimal dose and safety of the novel oral anti-viral molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study | Journal of Antimicrobial Chemotherapy | 27 August 2021 | Read more |
| Platform | AGILE: A Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment: An update to the structured summary of a study protocol for a randomised platform trial letter | Trials | 26 July 2021 | Read more |
| Platform | Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic | BMC Medical Research Methodology | 20 January 2022 | Read more |
| CST2 | The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva | Journal of Pharmaceutical and Biomedical Analysis | 02 September 2021 | Read more |
| CST3A | An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2 | Clinical Pharmacology & Therapeutics | 26 October 2021 | Read more |
| CST2 | Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection | Clinical Infectious Diseases | 10 March 2022 | Read more |
| CST2 | A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2 | The Lancet ID | 19 October 2022 | Read more |
| CST2 | Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial | Nature Communications | 26 November 2022 | Read more |
| CST6 | Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma | Journal of Pharmaceutical and Biomedical Analysis | 05 September 2023 | Read more |
| Platform | Application of novel plasma separation filter cards for quantification of NRTI di/triphosphates in DBS using LC-MS | Bioanalysis | 09 June 2023 | Read more |
| CST6 | A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5’-triphosphate (T-705-RTP) in human peripheral mononuclear cells | Journal of Pharmaceutical and Biomedical Analysis | 01 August 2024 | Read more |
| Platform | Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications | mSphere | 01 November 2024 | Read more |
